Highlights ALX Oncology Holdings Inc.

Equities

ALXO

US00166B1052

Real-time Estimate Cboe BZX Other stock markets 11:40:01 09/05/2024 pm IST			5-day change	1st Jan Change
17 ^USD	+2.35%		+2.35%	+14.24%

08/05	Alx Oncology Holdings Insider Sold Shares Worth $318,334, According to a Recent SEC Filing	MT
07/05	ALX Oncology Appoints Allison Dillon as Chief Business Officer	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ALX Oncology Holdings Inc. Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer	30/04	CI
ALX Oncology Reports Positive Data From Ongoing Phase 1/2 Trial of Evorpacept	10/04	MT
ALX Oncology Holdings Inc. Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (?R/R B-NHL?)	10/04	CI
North American Morning Briefing : Stock Futures -2-	11/03	DJ
ALX Oncology Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	08/03	CI
ALX Oncology Holdings Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	08/03	CI
ALX Oncology Reports Q3 Results With 'Sufficient' Funds to Finance Operations Into Early 2026	14/11	MT
ALX Oncology Q3 Net Loss Widens; Shares Ease After Hours	14/11	MT
ALX Oncology Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
ALX Oncology Holdings Inc. Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer	03/23/03	CI
ALX Oncology Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
ALX Oncology's Gastric Cancer Drug Receives European Commission's Orphan Drug Designation	26/23/26	MT
ALX Oncology Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Alx Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with Sarclisa (Isatuximab-Irfc) in Patients with Multiple Myeloma	25/23/25	CI
ALX Oncology Holdings Inc. and Quantum Leap Healthcare Collaborative Announces First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer	13/23/13	CI
ALX Oncology Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	10/23/10	CI
ALX Oncology Holdings Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	10/23/10	CI
ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer	16/23/16	CI
Alx Oncology Announces Initial Data from Aspen-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia	12/22/12	CI
ALX Oncology Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	09/22/09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ALX Oncology Holdings Inc.

Equities

ALXO

US00166B1052

Highlights

Filters